- Record: found
- Abstract: found
- Article: not found
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian
1 ,
F Stephen Hodi ,
Julie R Brahmer ,
Scott N Gettinger ,
David C Smith ,
David F McDermott ,
John D Powderly ,
Richard D Carvajal ,
Jeffrey A Sosman ,
Michael B Atkins ,
Philip D Leming ,
David R Spigel ,
Scott J Antonia ,
Leora Horn ,
Charles G Drake ,
Drew M Pardoll ,
Lieping Chen ,
William H Sharfman ,
Robert A Anders ,
Janis M Taube ,
Tracee L McMiller ,
Haiying Xu ,
Alan J Korman ,
Maria Jure-Kunkel ,
Shruti Agrawal ,
Daniel McDonald ,
Georgia D Kollia ,
Ashok Gupta ,
Jon M Wigginton ,
Mario Sznol
Jun 28 2012
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1.